ICON makes two senior appointments
pharmafile | May 21, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CRO, ICON, appointment
ICON has appointed Dr Susan Anton as director of epidemiology and risk management practice, and late phase and outcomes research.
It has also appointed Dr Pui Leung as its new senior clinical research physician, in ICON’s development solutions division.
Dr Anton comes to ICON with over 25 years of experience international epidemiologic, health economic, and outcomes research, and other market access initiatives.
She joins ICON from Boehringer Ingelheim, where she was director of US medical outcomes research and registries.
In this role, Dr Anton provided strategic approach, design and analytic guidance for comparative effectiveness research, epidemiologic studies and health technology assessment within their medical outcomes research and registries division.
Prior to Boehringer Dr Anton directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.
Dr Leung joins ICON with over 23 years of hospital and pharma industry experience in a variety of medical specialties including diabetes, endocrinology and general medicine.
Prior to ICON, Dr Leung gained 10 years of experience as a senior Phase I clinical research physician in two UK CROs, and has been principal investigator in many trials with a variety of different study designs including First in Human studies.
Before joining the pharma industry in 2002, Dr Leung spent 13 years as a hospital physician in the NHS.
Related Content
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
From molecule to market and beyond: Uniphar announces extended global commercialization platform
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
